#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Retatrutide + GHK-Cu + ipamorelin stack
What the research says about each compound and the key data gaps before combining retatrutide, GHK-Cu, and ipamorelin with CJC-1295 No DAC.
GLP-1 and GIP: a short incretin history
Incretins went from a failed 1906 diabetes experiment to GLP-1 and GIP drugs. Here are the dates, the discoveries, and where the evidence thins out.
GLP-1 safety in neuroendocrine tumours
A 2026 European Journal of Endocrinology review weighs the evidence on GLP-1 receptor agonists like semaglutide in neuroendocrine neoplasms.
MASLD and cardiovascular risk explained
MASLD affects 38% of adults worldwide and heart disease kills more of them than liver failure. Where semaglutide fits, and what remains unproven.
Tirzepatide and a rash: one case report
A 2026 JAAD case report links a year of tirzepatide to a widespread rash that cleared when the drug stopped. One patient is not a risk rate.
Why weight loss stalls on tirzepatide
A weight loss plateau is the expected shape of the tirzepatide curve, not a failure. Here is what the trials show and where retatrutide really stands.
Does the eGFR dip explain heart benefit?
A 376-patient Saudi cohort asked whether the early eGFR change explains heart outcomes on dapagliflozin plus semaglutide. The answer was no.
GLP-1 timing and pregnancy blood pressure
A 2026 meta-analysis of three cohorts found no significant link between GLP-1 use around conception and hypertensive disorders of pregnancy.
Semaglutide meta-analysis: what it adds
A 2026 pooled analysis of four semaglutide trials in non-diabetic obesity lands on almost exactly the number STEP 1 reported in 2021.
GLP-1 and mood drugs: reading the signal
A 2026 Australian study links GLP-1 starts to fewer antidepressant starts. The design behind it decides how much that finding is worth.
Tirzepatide and pancreatitis: one case
A 2026 case report describes tirzepatide used after recurrent hypertriglyceridemia-mediated pancreatitis. One patient is not evidence of safety.
Retatrutide and gray hair: evidence review
Community reports tie retatrutide to more gray hairs. No trial confirms this, but rapid weight loss can affect hair pigmentation in ways worth understanding.